We seek an enthusiastic PhD student for an industrial doctorate program on drug discovery (Small Molecule Therapeutics research unit). Our focus is the discovery of small molecules against targets of pharmaceutical interest. The PhD candidate will apply DNA-encoded chemical libraries to identify new hits, followed by the design, synthesis and purification of small molecules using standard and advanced organic synthetic procedures. The candidate will also perform hit validation (i.e., Fluorescence polarisation, Biacore, small molecule ELISA and/or enzymatic assays) to evaluate the biological activity of the synthesised compounds. Potentially, the PhD candidate will proceed with the most promising hits to test in vitro (cellular assays) and in vivo activity (e.g., in murine models of cancer).
This program will be carried out in Zurich laboratories in collaboration with a European University. The student will be trained to:
Applications need to include the candidate’s CV, a letter of motivation and 2 reference letters.
If you are interested, please send your application to firstname.lastname@example.org
Who we are
Philogen is a Swiss-Italian integrated biotechnology company founded in 1996, with the mission to develop innovative biopharmaceuticals for targeted therapy (http://www.philogen.com). Philochem AG is the R&D department of Philogen and it is located in Zurich. Philogen-Siena focuses on product optimisation/production according to GMP standards and on clinical trial investigations.